The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice-Reference-Cited by-同舟云学术

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

Published:2020-03-18 Issue:10 Volume:9 Page:3390-3399
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Parikh Sameer A.¹^ORCID,Achenbach Sara J.²,Call Timothy G.¹,Rabe Kari G.²,Ding Wei¹^ORCID,Leis Jose F.³,Kenderian Saad S.¹^ORCID,Chanan‐Khan Asher A.⁴,Koehler Amber B.¹^ORCID,Schwager Susan M.¹,Muchtar Eli¹,Fonder Amie L.¹,McCullough Kristen B.⁵,Nedved Adrienne N.⁵,Smith Matthew D.⁵,Slager Susan L.²,Kay Neil E.¹,Finnes Heidi D.⁵^ORCID,Shanafelt Tait D.⁶

Affiliation:

1. Division of Hematology Department of Medicine Mayo Clinic Rochester MN USA

2. Division of Biomedical Statistics & Informatics Mayo Clinic Rochester MN USA

3. Department of Hematology and Oncology Mayo Clinic Phoenix AZ USA

4. Division of Hematology and Oncology Mayo Clinic Jacksonville FL USA

5. Department of Pharmacy Mayo Clinic Rochester MN USA

6. Division of Hematology Stanford University School of Medicine Palo Alto CA USA

Funder

Pharmacyclics.

Publisher

Wiley

Subject